These results indicate that mutant IDH1 pharmacological inhibitors such as GSK321 could be repurposed to inhibit the proliferation of AR+ PCa cells even though they harbour wild‐type IDH1. The gene discussed is IDH1; the disease is posterior cortical atrophy.